At present, many preclinical and clinical studies of dapagliflozin, a selective SGLT2 inhibitor, have revealed that selective inhibition of SGLT2 is beneficial for type 2 diabetic patients independently of pancreatic β-cell function or insulin sensitivity, and that the kidney is a safe and effective target for treatment [20]. Here, SLC5A2 is linked to type 2 diabetes mellitus.